Investor Centre

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced that following positive results from phase 1b and long term toxicity studies, the company is now progressing to a phase 2 study of its oral anti-fibrotic pan-Lysyl Oxidase (LOX) inhibitor PXS-5505 for treatment of the rare bone cancer, myelofibrosis (MF).

• Multiple ascending dose stage of Phase 1 trial demonstrates a well-tolerated drug that effectively inhibits all enzymes in the lysyl oxidase family that are involved in fibrosis.
• Long term toxicity studies completed clearing the way for 6-month phase 2 studies in several cancers with opportunity to demonstrate disease modifying efficacy.
• Pre-clinical program, regulatory advice and opinion from leading clinicians supports progression into phase 2 study of myelofibrosis, a rare bone cancer with high unmet need and significant market opportunity.
• Pharmaxis advances its clinical stage pipeline in fibrosis that includes selective LOXL2 inhibitors (PXS-5382 and PXS-5338) for chronic fibrotic diseases like NASH and IPF, the oral pan-LOX inhibitor (PXS-5505) for acute fibrosis and cancer, and a topical pan-LOX inhibitor for scarring.